[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639557":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":44,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cirrhotic patients treated by β-lactams",null,"Patients with liver cirrhosis or impaired liver function (Child-Pugh grade B or C) treated by β-lactams",[13],"Drug: β-lactams",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","β-lactams","Participants receiving β-lactams were included.",[9],[21],{"name":22,"affiliation":5,"role":23},"Dayu Chen","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+862583106666","cdy_pharmacy@njglyy.com",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Nanjing","Jiangsu","210008","China",{"type":37,"coordinates":38},"Point",[39,40],118.77778,32.06167,{"lat":40,"lon":39},[43],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"type":23,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chen Dayu","Pharmacist in Charge","100639557",false,"NCT07612163","Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients","Clinical Efficacy and Population Pharmacokinetics of β-lactams in Patients With Liver Cirrhosis: A Retro-prospective Observational Study","Inclusion Criteria:\n\nAge over 18 years Chinese patient: male or female Liver cirrhosis Diagnosed as bacterial infection Treated by β-lactams Serum concentration determined during therapy\n\nExclusion Criteria:\n\nDuration of β-lactams treatment less than 48 hours Patients renal or liver function not tested before treatment started Using more than two kinds of β-lactams","ALL","18 Years",{"count":56,"type":57},1000,"ESTIMATED","OBSERVATIONAL","Patients may benefit from the personalized β-lactams dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review, prospective observe and analyze the clinical outcomes of patients with liver cirrhosis, and to build a population pharmacokinetics model in the population mentioned above.",[61],"Bacterial Infections",[63,61,64],"β-lactam","Liver cirrhosis","2026-05-21",{"date":67,"type":68},"2026-05-28","ACTUAL",{"date":70,"type":68},"2023-12-31",{"date":72,"type":57},"2027-12-31",{"name":5,"class":6},1]